Nintedanib (BIBF 1120) for IPF: A tomorrow therapy?

Multidisciplinary Respiratory Medicine

Volumn 7, Issue 6, 2012, Pages

  Antoniu, Sabina A ^a  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Basic fibroblast growth factor; Idiopathic pulmonary fibrosis; Inhibitor; Platelet derived growth factor; Tyrosine kinase; Vascular endothelial growth factor

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; IMATINIB; NINTEDANIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE; VASCULOTROPIN;

DIARRHEA; DISEASE COURSE; DRUG WITHDRAWAL; FIBROGENESIS; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION; LUNG NON SMALL CELL CANCER; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; OXYGEN SATURATION; PATHOGENESIS; QUALITY OF LIFE; REVIEW; SURVIVAL; TOTAL LUNG CAPACITY; VOMITING;

EID: 84876579887     PISSN: 1828695X     EISSN: 20496958     Source Type: Journal    
DOI: 10.1186/2049-6958-7-41     Document Type: Review

References (16)

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Muller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schunemann HJ: Fibrosis AEJACoIP. An official ats/ers/jrs/alat statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183:788-824.
2. Spagnolo P, Del Giovane C, Luppi F, Cerri S, Balduzzi S, Walters EH, D'Amico R, Richeldi L: Non-steroid agents for idiopathic pulmonary fibrosis. Database Syst Rev 2010, 9:CD003134.
3. Leask A: Potential therapeutic targets for cardiac fibrosis. Circ Res 2010, 106:1675-1680.
4. Burns WC, Thomas MC: The molecular mediators of type 2 epithelial to mesenchymal transition (EMT) and their role in renal pathophysiology. Expert Rev Mol Med 2010, 12:e17.
5. Kerbel RS: Tumor angiogenesis. N Engl J Med 2008, 358:2039-2049.
6. Gotink KJ, Verheul HM: Anti-angiogenic tyrosine kinase inhibitors: What is their mechanism of action? Angiogenesis 2010, 13:1 -14.
7. Inoue Y, King TE, Barker E, Daniloff E, Newman LS: Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis. Am J Respir Crit Care Med 2002, 166:765-773. (Pubitemid 34971864)
8. Lo Re S, Lecocq M, Uwambayinema F, Yakoub Y, Delos M, Demoulin J-B, Lucas S, Sparwasser T, Renauld J-C, Lison D, Huaux F: Platelet-derived growth factor-producing cd4+ foxp3+ regulatory t lymphocytes promote lung fibrosis. Am J Respir Crit Care Med 2011, 184:1270-1281.
9. Antoniu SA, Kolb MR: Intedanib, a triple kinase inhibitor of vegfr, fgfr and pdgfr for the treatment of cancer and idiopathic pulmonary fibrosis. I Drugs 2010, 13:332-345.
10. Vuorinen K, Gao F, Oury TD, Kinnula VL, Myllarniemi M: Imatinibmesylate inhibits fibrogenesis in asbestos-induced interstitial pneumonia. Exp Lung Res 2007, 33:357-373. (Pubitemid 47396405)
11. Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR, Imatinib IPFSI: Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med 2010, 181:604-610.
12. Chaudhary NI, Roth GJ, Hilberg F, Muller-Quernheim J, Prasse A, Zissel G, Schnapp A, Park JE: Inhibition of pdgf, vegf and fgfsignalling attenuates fibrosis. Eur Respir J 2007, 29:976-985. (Pubitemid 46711904)
13. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G, Brun M, Gupta A, Juhel N, Kluglich M, du Bois RM: Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011, 365:1079-1087.
14. Brown KK RL, Costabel U, Flaherty KR, Kim D, Noble PW, Raghu G, Selman M, Brun M, Klueglich M, Staines H, du Bois RM, on behalf of the TOMORROW trial investigators: Treatment of IPF with the tyrosine kinase inhibitor bibf 1120: Patient-reported outcomes in the tomorrow trial. Am J Respir Crit Care Med 2012, 185: A3634.
15. Roll over study from 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF): ClinicalTrials.gov Identifier: NCT01170065; 2012.
16. Safety and efficacy of BIBF 1120 at high dose in Idiopathic Pulmonary Fibrosis patients: ClinicalTrials.gov Identifier:NCT01335464; 2012.